Arrowhead Research (ARWR) to Discontinue ARC-520, ARC-521, and ARC-AAT Development; Will Cut Workforce
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/19/2024
- Nasdaq, S&P tumble as Netflix, chip stocks drag; AmEx boosts Dow
- Sony/Apollo bid for Paramount could be worth as much as $29 billion - Source
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Nasdaq tumbles, Treasuries dip amid earnings, geopolitical crosscurrents
- Gold prices rally past $2,400 on reports of Israel strikes on Iran
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Jabil falls after placing CEO on paid leave amid internal investigation
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- Ibotta (IBTA) Prices 6.56M Share IPO at $88/sh
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
Arrowhead Research (ARWR) to Eliminate Chief Scientific Officer Position
December 1, 2016 4:58 PM ESTArrowhead Research (NASDAQ: ARWR) notified David Lewis, the Companys Chief Scientific Officer, that his position will be terminated, effective December 13, 2016.
This follows recent news that the company will be discontinuing development of its clinical stage drug candidates ARC-520, ARC-521, and ARC-AAT, which... More
William Blair Downgrades Arrowhead Research (ARWR) to Market Perform
November 30, 2016 8:23 AM ESTWilliam Blair downgraded Arrowhead Research (NASDAQ: ARWR) from Outperform to Market Perform.
For an analyst ratings summary and ratings history on Arrowhead Research click here. For more ratings news on Arrowhead Research click here.
Shares of Arrowhead Research closed at $4.39 yesterday.
... MoreArrowhead Research (ARWR) PT Slashed to $2 at Jefferies
November 30, 2016 8:12 AM ESTJefferies analyst Eun Yang lowered his price target on Arrowhead Research (NASDAQ: ARWR) to $2.00 (from $5.00) while maintaining a Hold rating after the company discontinues its EX1-based clinical programs (ARC-520, ARC-521, ARC-AAT) given likely "substantial" delays due to need for add'l non-clinical studies due... More
Cantor Fitzgerald Downgrades Arrowhead Research (ARWR) to Hold
November 30, 2016 6:58 AM ESTCantor Fitzgerald downgraded Arrowhead Research (NASDAQ: ARWR) from Buy to Hold with a price target of $1.00 (from $15.00).
For an analyst ratings summary and ratings history on Arrowhead Research click here. For more ratings news on Arrowhead Research click here.
Shares of Arrowhead Research closed at $4.39 yesterday.
... MorePiper Jaffray Downgrades Arrowhead Research (ARWR) to Neutral
November 30, 2016 6:57 AM ESTPiper Jaffray downgraded Arrowhead Research (NASDAQ: ARWR) from Overweight to Neutral with a price target of $2.00 (from $10.00).
For an analyst ratings summary and ratings history on Arrowhead Research click here. For more ratings news on Arrowhead Research click here.
Shares of Arrowhead Research closed at $4.39 yesterday.
... MoreChardan Capital Markets Downgrades Arrowhead Research (ARWR) to Neutral on EX-1 RNAi Program Discontinuations
November 30, 2016 6:19 AM ESTChardan Capital Markets downgraded Arrowhead Research (NASDAQ: ARWR) from Buy to Neutral with a price target of $2.00 (from $8.00) on EX-1 RNAi program discontinuations.
Analyst Madhu Kumar commented, "As previously highlighted, the Bear Case for ARWR has occurred, with broad loss of the EX-1 based clinical pipeline. In our 10 November 2016 company note, we highlighted both bullish and bearish scenarios for... More
Arrowhead Research (ARWR) sinks 69% as trading resumes
November 29, 2016 4:31 PM ESTArrowhead Research (NASDAQ: ARWR) sinks 69% as trading resumes.
... More
